“…In 2006, the concentration was raised to 6.6%, and this TDM has been patch tested not only in Sweden and Belgium , but also in seven dermatology departments in Sweden , and in 12 clinics in nine countries in Europe and the United States . The frequencies of TDM‐positive patients were 3.7% in the European/US study and 2.5% in the Swedish study , with overall clinical relevance of 31% and 37%, respectively. In the recent Swedish study encompassing seven dermatology departments from all over Sweden, a TDM at 8.0% was tested in parallel, and this mix picked up 2.8% of those allergic to this mix, in contrast to 2.5% for the 6.6% mix .…”